Enal Razvi's Biography

Enal Razvi, Managing Director, Select Biosciences Inc

Enal Razvi, PhD is biotechnology analyst and Managing Director US at Select Biosciences. In this capacity he continuously tracks a number of fields in the scope of his industry coverage, authors market analysis reports in these areas, and works with companies worldwide in the areas of technology analysis, market research, strategy development, and operational roles. Dr. Razvi holds a doctoral degree in the biomedical sciences and was post-doctoral fellow under Ralph Steinman [Nobel Laureate in 2011] at The Rockefeller University, New York. For the last decade, Dr. Razvi has been focused on tracking the life sciences fields and has worked with numerous companies around the world.

Dr. Razvi can be reached at: enal@selectbio.us

Exosomes and MicroRNA: Research and Translational Research Opportunities

Wednesday, 13 November 2013 at 14:15

Add to Calendar ▼2013-11-13 10:45:002013-11-13 11:45:00Europe/LondonCancer Biomarkers: A Market Landscape and Publication Trends AnalysisGenomics Research Asia in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com

Select Biosciences has been tracking closely the exosomes and microRNAs marketplace based on end-user research trends both qualitative as well as quantitative. This analysis frames the current research space, offers opportunities to companies to develop products, and frames opportunity for these biomarker classes to be validated and deployed as diagnostics for the future. In this presentation, I will also frame the market opportunity for other classes of circulating biomarkers since these markets are evolving in parallel with the exosomes space.

Cancer Biomarkers: A Market Landscape and Publication Trends Analysis

Wednesday, 13 November 2013 at 10:45

This presentation frames the broader market landscape for cancer biomarkers evaluated utilizing a number of industry metrics. We have utilized computational approaches to analyze the full cancer biomarkers publications space and this allows us to visualize publications trends as well as identify associations of specific molecular entities with various disease classes. We have performed an extensive analysis of the cancer biomarkers field and have found specific patterns of association with breast cancer for instance. This analysis is scalable as it is applicable to various classes and can be utilized as a means to predict biomarker associations which can then be experimentally-validated using retrospectively- or prospectively-isolated clinical samples. We also compare in this analysis traditional biomarkers (protein-based) with nucleic acid-based biomarkers arising from genomics-based discovery projects.

Add to Calendar ▼2013-11-12 00:00:002013-11-13 00:00:00Europe/LondonGenomics Research AsiaGenomics Research Asia in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors